Stemline Therapeutics Reports Second Quarter 2019 Financial Results
Net revenue for ELZONRIS® was $13.0 million for the second quarter Conference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage …